HIGHLY RELIABLE MONOCLONAL ANTIBODIES
Unique features of the monoclonal antibodiesAtlas Antibodies are there to help you choose the right monoclonal antibody for your needs. Rather than offering numerous products to the same tar-get, we make sure to select only the most relevant antibodies to each tar-get.
Atlas Antibodies take special care in offering clones recognizing only unique non-overlapping epitopes and/or isotypes. Using the same stringent production process and characteri-zation procedure as for our Triple A Polyclonals, our monoclonal antibod-ies offer outstanding performance in approved applications, together with defined specificity, secured continu-ity and stable supply. In general they also permit higher working dilutions and contribute to more standardized assay procedures.
Antigen SelectionThe Protein Epitope Signature Tag (PrEST) concept gives you antibody performance built in from the start. Using proprietary bioinformatics soft-ware, 50-150 amino acid regions with the lowest possible sequence identity to other human proteins are selected, cloned and recombinantly produced in a tightly controlled set-up.
Clone SelectionFunctional characterization is per-formed on a large number of ELISA positive cell supernatants to select the optimal clones for each applica-tion prior to subcloning and expan-sion of selected Hybridomas.
Epitope MappingClones are epitope-mapped using synthetic overlapping peptides in a bead-based array format for selec-tion of clones with non-overlapping epitopes only.
IsotypingAll our monoclonal antibodies are iso-typed to allow for multiplexing using isotype-specific secondary antibod-ies.
Hybridoma Cell CultivationFor ethical reasons Atlas Antibodies uses only in-vitro methods for the pro-duction scale-up phase thus replac-ing the use of mice for production of ascites fluid.
Antibody CharacterizationThe characterization of Atlas Antibod-ies Monoclonal Antibodies starts with an extensive literature search to se-lect the most relevant and clinically significant tissues to use for immu-nohistochemistry (IHC) characteriza-tion. You will often find more than one tissue type displayed in the IHC appli-cation data in our product catalog. In addition to positive stained tissue we also display a negative control tissue staining and if relevant clinical cancer tissue staining.
The characterization for Western blot (WB) data follows that same work-ing procedure and starts with a pro-found literature search to find the best matching lysate, which can be endog-enous human cell or tissue protein lysates or optionally recombinant full-length human protein lysates.
Each monoclonal antibody is thus supplied with the most relevant char-acterization data for its specific target.
.
Monoclonal Antibodies at Atlas Antibodies
The Anti-VIM (Vimentin) antibody (AMAb90516) shows strong positivity in mesenchymal and lymphoid cells in human rectum using immunohisto-chemical staining.
The Anti-DICER1 antibody (AMAb90737) shows cytoplasmic immunoreactivity in the glandular epi-thelium cells in human uterus using immunohistochemical staining.
The Anti-SIX1 antibody (AMAb90544) shows strong nuclear immunoreactiv-ity in the myocytes in human striated muscle using immunohistochemical staining.
Monoclonal Antibody Development ProgramResearch remains at the heart of At-las Antibodies. We welcome custom-ers to contact us for possible collabo-rations on both existing and future product offerings. One of our collabo-ration programs aims at developing monoclonal antibodies in collabora-tion with our customers.
Atlas Antibodies encourage you to participate in our Monoclonal Anti-body Development Program for hu-man targets. If you are looking for monoclonal antibodies currently not available in our catalog, and if you are interested in developing the antibody together with us, please send in your request to us.
Upon agreement to proceed with a collaboration, Atlas Antibodies will develop and produce the monoclonal antibody using our standardized pro-
cedures. Within this procedure we al-ways epitope map all our clones and this will give you the possible option to obtain multiple clones with unique binding specificity. The selection of the optimal clones will be done in col-laboration with you. Antibodies can either be sent to you for additional characterization in your laboratory or Atlas Antibodies can make the char-acterization at our facilities with our expert input and/or material. Atlas An-tibodies cover all other development costs. If the project results in a com-mercialized product it will be added to Atlas Antibodies Monoclonal prod-uct portfolio and available to you for a special discount price. All our final products will be stained and annotat-ed by the Human Protein Atlas (HPA) project and these results will be avail-able on the HPA web portal.
Benefits of the program Atlas Antibodies take the full develop-ment cost while you get a discounted antibody with proven functionality in your experimental set-up.
For more information and/or requests for participating in the program, you are welcome to contact us at [email protected].
We are looking forward to hearing from you.
Collaboration project for SOX11The mouse monoclonal Anti-SOX11 antibodies AMAb90501 and AMAb90502 were developed in col-laboration with Dr Antonio Martinez (Laboratory of Pathology, Hospi-tal Clínic, University of Barcelona, Spain).
Dr Martinez is involved in the study of aggressive lymphomas, mecha-nisms of transformation, progres-sion and prognostic factors. He has collaborated in the description of transcription factors involved in B-cell development and lymphom-agenesis with special emphasis in those related in late B-cell differenti-ation pathways such as IRF4, IRF8, XBP1 and SOX11. His lab has long expertise in the characterization of antibodies for clinical use in he-matopathology.
SOX11This gene encodes a member of the group C SOX (SRY-related HMG-box) transcription factor fam-ily involved in the regulation of em-bryonic development and in the determination of the cell fate. The encoded protein may act as a tran-scriptional regulator after forming a protein complex with other pro-teins. The protein may function in the developing nervous system and play a role in tumorigenesis and adult neurogenesis. Diseases as-sociated with SOX11 include mantle cell lymphoma (MCL), lymphoblas-tic lymphoma, Burkitt lymphoma and malignant glioma. The diag-nosis of mantle cell lymphoma can be difficult, especially in Cyclin D1 negative cases and the transcrip-tion factor SOX11 may serve as an important diagnostic marker. For this purpose, there is a need of a reliable Anti-SOX11 antibody in the clinical setting.
Tonsil involved by a Classical Mantle cell lympho-ma, cyclin D1 negative in a 50 yo male. SOX11 staining (AMAb90501, clone CL0142; Atlas Anti-bodies).
Lymph node involvement by Classical Mantle cell lymphoma positive for Cyclin D1 in a 64 yo male. SOX11 is expressed in virtually all tumor cells. (AMAb90502, clone CL0143; Atlas Antibodies).
Soldini D et al. Assessment of SOX11 Expression in Routine Lymphoma Tissue Sections: Characteri-zation of New Monoclonal Antibodies for Diagnosis of Mantle Cell Lymphoma. Am J Surg Pathol. 2013 Oct 18.
Collaboration project forPLA2R1The PLA2R (PLA2R1) is a trans-membrane receptor belonging to the mannose receptor family and a receptor for the secreted phos-pholipase A2, a lipolytic enzyme that cleaves the fatty acid bond of membrane glycerophospholipids. A common functional feature of this family of receptors is their ability to undergo endocytosis and thus be involved in the internalization of extra-cellular ligands. The PLA2R protein likely exists both in a trans-membranous and a soluble form. The M-type phospholip-ase A2 re-ceptor (PLA2R) has been identified as a major target antigen involved in
idiopathic membranous nephropa-thy in adults.
Our mouse monoclonal Anti-PLA2R1 (AMAb90775) antibody was developed in collaboration with Dr Hanna Debiec.
Dr Hanna Debiec was trained in bio-chemistry, cell biology, and physiol-ogy. She is one of the leaders in the field of membranous nephropathy (MN) and is working as a scientific director in the immunopathology research team of Professor Pierre Ronco. This Research team has made several discoveries on the pathogenesis of MN.
Collaboration project forSCGN, NECAB1 and NE-CAB2The monclonal antibodies Anti-SCGN (AMAb90630), Anti-NECAB1 (AMAb90801) and Anti-NECAB2 (AMAb90808) have been devel-oped in collaboration between Dr Jan Mulder (SciLifeLab Stockholm, Sweden) and Atlas Antibodies.
Dr Mulder´s group performs anti-body based profiling of proteins in the human and rodent nervous sys-tem using biochemical and immuno-fluorescence techniques in combi-nation with automated microscopy. The aim is to quantify and visualize regional, cellular and subcellular distribution of proteins in the devel-oping, healthy and diseased nerv-ous system.
In collaboration with the Human Protein Atlas (HPA) project, utilizing the unique antibody resource cre-ated within the project, they aim to 1) investigate protein distribution in a large portion of the nervous sys-
tem using the smaller rodent brain and 2) identify changes in protein expression and distribution in the human brain affected by neurode-generative disorders.
Shi TJ et al. Secretagogin is expressed in sensory CGRP neurons and in spinal cord of mouse and complements other calcium-binding proteins, with a note on rat and human. Mol Pain 2012 Oct 29;8:80
Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephrop-athy. N Engl J Med 2011 Feb 17;364(7):689-90.
Debiec H et al. Autoantibodies Specific for the Phos-pholipase A(2) Receptor in Recurrent and De Novo Membranous Nephropathy. Am J Transplant 2011 Oct;11(10):2144-52.
IF staining of paraffin embedded kidney biopsy specimen from patient with membranous nephrop-athy using the monoclonal Anti-PLA2R1 antibody AMAb90775.
IF staining of mouse hypothalamus using. Distribu-tion of NECAB1 (green) in the mouse dorsal medial thalamus. The monoclonal Anti-NECAB1 antibody AMAb90801 strongly labels neurons and their pro-cesses in the paraventricular and mediodorsal tha-lamic nuclei. Blue is the nuclear staining Hoechst.
Immunohistochemical staining of human pancreas shows strong cytoplasmic and nuclear immunore-activity in the islets of Langerhans.
RBM3 - A prognostic and treatment predictive biomarker The RNA-binding protein RBM3 has been identified via the Human Pro-tein Atlas as an oncology biomarker through the differential expression pattern observed within several in-vestigated cancers.
In general, the levels of RBM3 ex-pression have been found to have a significant correlation to patient sur-vival in breast, colon, ovarian, testi-cular, prostate and urothelial cancer as well as in malignant melanoma. The monoclonal Anti-RBM3 antibo-dy AMAb90655 has shown excellent specificity in Western blot analysis and is routinely used for staining of formalin fixed paraffin embedded tis-sues in IHC.
A major clinical challenge in urothe-lial cancer is the identification of high-risk patients among those di-agnosed with non-invasive disease. Our data suggests that RBM3 ex-pression analysis could be used as a prognostic factor for better stratification of patients, leading to a more individualized treatment of patients with urothelial cancer. The prognostic significance of RBM3 in urothelial cancer has been confir-
med in several independent cohorts.Our findings indicate that patients whose tumors express high levels of RBM3 could benefit from platinum-based treatment, whereas alterna-tive treatments may be considered for patients having no or low RBM3 expression. In vitro cell-line expe-riments have also demonstrated a role of RBM3 in respect to treatment with platinum-based drugs like cisp-latin. This has been further validated in a colorectal cancer cohort where patients with tumors expressing high levels of RBM3 showed a markedly increased survival upon platinum adjuvant treatment compared to pa-tients receiving no- or non-platinum based adjuvant treatment.
Need for Novel Cancer Biomarkers The microscopic evaluation of stained tissue sections from a tumor remains the gold standard for cancer diag-nosis. However, in order to optimize patient treatment and provide guid-ance for therapeutic intervention of the underlying disease there is often a need for additional tumor stratifica-tion methods.
The analysis of protein expression in cells from a tumor tissue often pro-vides important additional information to the responsible pathologist. Immu-nohistochemistry (IHC) using protein specific antibodies provides a tool to detect the presence, abundance and localization of specific proteins.
With a limited repertoire of protein biomarkers available today there is a clear and unmet clinical need to identi-fy novel sets of biomarkers. The needs are both to provide a more accurate diagnosis and a better assessment of patient prognosis, ultimately leading to a more individualized treatment.
Atlas Antibodies recognize this need for new biomarkers. Together with our research partners in the Human Pro-tein Atlas project we are in a unique position to perform antibody-based biomarker discovery.
Biomarkers for LicensingAtlas Antibodies currently have seve-ral proprietary oncology biomarkers. These are now available for licensing together with the accompanying mo-noclonal antibodies. An overview of a few selected biomarkers is given be-low.
For additional information on licensing of specific biomarkers, or if you would like to know more about Atlas Antibo-dies customized solutions and valida-tion capabilities, please contact us directly at [email protected] or visit our Research Collaborations page (atlasantibodies.com/research/collaborations).
Survival analysis of urothelial cancer patients strati-fied according to RBM3 expression.
Representative nuclear staining of RBM3 in urothe-lial cancer, with no RBM3 expression (A), intermedi-ate RBM3 expression (B) and high RBM3 expression (C) respectively. Immunohistochemistry analysis is performed using the monoclonal Anti-RBM3 antibody AMAb90655.
Related PublicationsEhlén A et al. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med. 2010 Aug 20;8:78.
Hjelm B et al. High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer. Proteomics Clin Appl. 2011 Dec;5(11-12):624-35.
Boman K et al. Decreased expression of RNA-binding motif pro-tein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. BMC Urol. 2013, 13:17.
Oncology Biomarkers
PODXL - An independent factor for poor prognosis and treatment stratificationPodocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has been associ-ated with aggressive tumor pheno-type and adverse outcome in sev-eral cancer types.
In a number of recently published papers, Larsson et al have demon-strated that membraneous expres-sion of PODXL is associated with unfavourable clinicopathological characteristics and independently predicts a poor prognosis in colo-rectal cancer (CRC). This has been demonstrated in three independent patient cohorts in total comprising more than 1,000 patients. The re-sults clearly demonstrate the poten-tial utility of PODXL as a biomarker for more precise prognostication and treatment stratification in CRC.
Boman et al have investigated the prognostic impact of membraneous PODXL expression in almost 500
cases of urothelial cancer. They con-cluded that PODXL is indeed an in-dependent risk factor for progressive disease and death in patients with urothelial cancer and that this war-rant further studies to fully evaluate the use of PODXL as a biomarker for improved treatment stratification of bladder cancer patients.
SATB2 – A diagnostic biomarker for tumors of colorectal originCell- and cancer-type specific pro-teins are rare. The special AT-rich sequence-binding protein SATB2 has been identified as having a very selective expression pattern. In cells of epithelial lineages, SATB2 is expressed in glandular cells lin-ing the lower gastrointestinal tract and expression is retained in a large majority of primary and metastatic colorectal cancers. Thus, SATB2 is a promising diagnostic biomarker for tumors of colorectal origin.
In a previously published study by Magnusson et al it was shown, by analyzing more than 1,800 tumor samples, that SATB2 expression is largely preserved in cells of colorect-lal cancer origin. More than 85% of all colorectal cancers showed distinct SATB2 immunostaining and when used in combination with Cytokeratin 20 analysis, SATB2 identified more than 95% of all tumors with colorectal origin.
These promising data suggested that the combination of SATB2 and CK20 should be tested in an unbi-ased clinical study to further validate the initial findings. In a recent pub-lication by Dragomir et al, the ex-pression of SATB2 was analyzed in over 800 consecutive clinical cases for which CK20 immunostaining was considered necessary to obtain a fi-nal diagnosis. In this study, SATB2 showed 93% sensitivity and 77% specificity to determine a cancer of colorectal origin and in combination with CK7 and CK20, the specific-ity increased to 100%. SATB2 thus provides a new and advantageous supplement to current standards for clinical differential diagnosis.
In Atlas Antibodies´ product cata-log, there are five monoclonal Anti-SATB2 antibodies recommended for IHC and WB analysis. Related Publications
Magnusson K et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011 Jul;35(7):937-48.
Dragomir A et al. The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results from a pathology-based clinical prospective study. Am J Clin Pathol. 2013 In press.
C D
A B
Immunohistochemical staining of PODXL protein in colorectal tumor tissue using A) HPA002110, B) AMAb90643, C) AMAb90644 and D) AMAb90667 antibodies.
Kaplan–Meier estimates of 5-year Overall Survival (OS) according to PODXL expression in a urothe-lial cancer patient cohort of 110 individuals.
Immunohistochemical staining of human colorec-tal tumor with Anti-SATB2 antibody (AMAb90635) shows strong nuclear staining in tumor cells.
Related PublicationsLarsson A et al. Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer 2011 Aug 23;105(5):666-72.
Larsson A et al. Validation of podocalyxin-like protein as a bio-marker of poor prognosis in colorectal cancer. BMC Cancer. 2012 Jul 8;12:282.
Boman K et al. Membraneous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer. Br J Cancer. 2013 Jun 11;108(11),
Mouse Monoclonal Antibodies
Anti-ADARProduct Name Anti-ADAR
Product Number AMAb90535
Isotype IgG1
Validated Applications
IHC, WB
Anti-ACSL5Product Name Anti-ACSL5
Product Number AMAb90634
Isotype IgG1
Validated Applications
IHC, WB
Anti-ANLN/Anillin Product Name Anti-ANLN
Product Number AMAb90660
Isotype IgG1
Validated Applications
IHC, WB
Epitope PSKGELSREICLQSQ
Anti-ANXA1/Annexin A1Product Name Anti-ANXA1
Product Number AMAb90558
Isotype IgG1
Validated Applications
IHC, WB
Epitope PQLRRVFQKY
Anti-APOA4Product Name Anti-APOA4
Product Number AMAb90767
Isotype IgG2a
Validated Applications
IHC, WB
Epitope LRQRLAPLAEDVRGN
Anti-AKT1Product Name Anti-AKT1
Product Number AMAb90834
Isotype IgG1
Validated Applications
WB
Epitope FEYLKLLGKGTFGKV
Anti-AKT1Product Name Anti-AKT1
Product Number AMAb90835
Isotype IgG1
Validated Applications
WB
Epitope ILVKEKATGRYYAMK
Anti-ANLN/Anillin Product Name Anti-ANLN
Product Number AMAb90662
Isotype IgG1
Validated Applications
IHC, WB
Epitope LRGRFDKGNIWSAEK
Anti-APOA4Product Name Anti-APOA4
Product Number AMAb90768
Isotype IgG1
Validated Applications
IHC, WB
Epitope EQLRQKLGPHAGDVE
Anti-APOA4Product Name Anti-APOA4
Product Number AMAb90769
Isotype IgG1
Validated Applications
IHC, WB
Epitope GHLSFLEKDL
Anti-ATRXProduct Name Anti-ATRX
Product Number AMAb90784
Isotype IgG1
Validated Applications
IHC
Anti-APOL1Product Name Anti-APOL1
Product Number AMAb90529
Isotype IgG1
Validated Applications
WB
Epitope ESGEQVERVN
Anti-AQP4/Aquaporin 4Product Name Anti-AQP4
Product Number AMAb90537
Isotype IgG1
Validated Applications
IHC, WB
Anti-ARG1/Arginase 1Product Name Anti-ARG1
Product Number AMAb90545
Isotype IgG1
Validated Applications
IHC, WB
Anti-ATAD2Product Name Anti-ATAD2
Product Number AMAb90541
Isotype IgG1
Validated Applications
IHC, WB
Epitope VGDKRSDPEQ
Anti-ATP6AP2/Renin receptorProduct Name Anti-ATP6AP2
Product Number AMAb90588
Isotype IgG1
Validated Applications
IHC
Anti-APOL1Product Name Anti-APOL1
Product Number AMAb90530
Isotype IgG1
Validated Applications
IHC, WB
Epitope AEELKKVAQELEEKL
Anti-APOL1Product Name Anti-APOL1
Product Number AMAb90532
Isotype IgG1
Validated Applications
WB
Epitope GIGKDIRALR
Anti-BRD4Product Name Anti-BRD4
Product Number AMAb90841
Isotype IgG1
Validated Applications
IHC, WB
Epitope PQPAKPQQVIQHHHS
Anti-BRD4Product Name Anti-BRD4
Product Number AMAb90843
Isotype IgG1
Validated Applications
IHC, WB
Epitope EAPSPLMIHSPQMSQ
Anti-CA12
Anti-CD4Product Name Anti-CD4
Product Number AMAb90754
Isotype IgG1
Validated Applications
IHC
Anti-CD45/PTPRCProduct Name Anti-CD45
Product Number AMAb90518
Isotype IgG1
Validated Applications
IHC, WB
Epitope LNLDKNLIKY
Anti-CD45/PTPRCProduct Name Anti-CD45
Product Number AMAb90519
Isotype IgG2a
Validated Applications
IHC, WB
Epitope LNLDKNLIKY
Anti-CHGA/Chromogranin AProduct Name Anti-CHGA
Product Number AMAb90525
Isotype IgG1
Validated Applications
IHC, WB
Epitope HSGFEDELSEVLENQ
Anti-CNDP1Product Name Anti-CNDP1
Product Number AMAb90698
Isotype IgG1
Validated Applications
WB
Epitope DEFVQTLKEWVAIES
Anti-CTCFProduct Name Anti-CTCF
Product Number AMAb90663
Isotype IgG2a
Validated Applications
IHC, WB
Epitope AYENEVSKEG
Anti-CA12Product Name Anti-CA12
Product Number AMAb90637
Isotype IgG2a
Validated Applications
IHC, WB
Epitope HLQHVKYKGQEAFVP
Anti-KIT/CD117Product Name Anti-KIT
Product Number AMAb90900
Isotype IgG1
Validated Applications
WB
Epitope DPGFVKWTFE
Anti-KIT/CD117Product Name Anti-KIT
Product Number AMAb90901
Isotype IgG1
Validated Applications
IHC, WB
Epitope ILDETNENKQNEWIT
Product Name Anti-CA12
Product Number AMAb90639
Isotype IgG1
Validated Applications
IHC, WB
Epitope HLQHVKYKGQEAFVP
Anti-CTCF
Anti-CTCF
Product Name Anti-CTCF
Product Number AMAb90664
Isotype IgG1
Validated Applications
IHC, WB
Epitope NMEEQPINIGELQLV
Product Name Anti-CTCF
Product Number AMAb90666
Isotype IgG2b
Validated Applications
IHC, WB
Epitope TLPLPEGFQV
Anti-EMD/EmerinProduct Name Anti-EMD
Product Number AMAb90560
Isotype IgG2a
Validated Applications
IHC, WB
Epitope DALLYQSKGYNDDYY
Anti-DICER1Product Name Anti-DICER1
Product Number AMAb90737
Isotype IgG2a
Validated Applications
IHC
Anti-DOCK8Product Name Anti-DOCK8
Product Number AMAb90611
Isotype IgG1
Validated Applications
IHC, WB
Anti-DIAPH2Product Name Anti-DIAPH2
Product Number AMAb90856
Isotype IgG1
Validated Applications
IHC, WB
Epitope SLNLSEKEVLDLFEK
Anti-DIAPH2Product Name Anti-DIAPH2
Product Number AMAb90857
Isotype IgG1
Validated Applications
IHC, WB
Epitope IKTLADDVRDRITSF
Anti-EGFR/ERBBProduct Name Anti-EGFR
Product Number AMAb90816
Isotype IgG1
Validated Applications
IHC, WB
Epitope RTDLHAFENL
Anti-EGFR/ERBBProduct Name Anti-EGFR
Product Number AMAb90819
Isotype IgG1
Validated Applications
WB
Epitope DSFTHTPPLD
Anti-EMD/EmerinProduct Name Anti-EMD
Product Number AMAb90562
Isotype IgG1
Validated Applications
IHC, WB
Epitope QSKGYNDDYY
Anti-FABP7Product Name Anti-FABP7
Product Number AMAb90595
Isotype IgG1
Validated Applications
IHC, WB
Anti-FBN1/Fibrillin-1Product Name Anti-FBN1
Product Number AMAb90584
Isotype IgG2b
Validated Applications
IHC, WB
Anti-FBN1/Fibrillin-1Product Name Anti-FBN1
Product Number AMAb90585
Isotype IgG1
Validated Applications
IHC
Anti-FLT1/VEGFR-1Product Name Anti-FLT1
Product Number AMAb90704
Isotype IgG2b
Validated Applications
IHC, WB
Anti-HER2/ERBB2Product Name Anti-HER2
Product Number AMAb90627
Isotype IgG1
Validated Applications
IHC, WB
Anti-FUSProduct Name Anti-FUS
Product Number AMAb90549
Isotype IgG1
Validated Applications
IHC, WB
Anti-GDF15Product Name Anti-GDF15
Product Number AMAb90687
Isotype IgG1
Validated Applications
IHC, WB
Anti-HDAC1Product Name Anti-HDAC1
Product Number AMAb90781
Isotype IgG1
Validated Applications
IHC, WB
Anti-FBLN1/Fibulin 1Product Name Anti-FBLN1
Product Number AMAb90696
Isotype IgG1
Validated Applications
IHC, WB
Anti-FLT1/VEGFR-1Product Name Anti-FLT1
Product Number AMAb90703
Isotype IgG1
Validated Applications
IHC
Anti-IDH1Product Name Anti-IDH1
Product Number AMAb90578
Isotype IgG2a
Validated Applications
IHC, WB
Epitope IEDFAHSSFQMALSK
Anti-MEF2CProduct Name Anti-MEF2C
Product Number AMAb90728
Isotype IgG1
Validated Applications
IHC, WB
Epitope NLLPLAHPSL
Anti-HNF1BProduct Name Anti-HNF1B
Product Number AMAb90733
Isotype IgG1
Validated Applications
IHC, WB
Anti-KDM5BProduct Name Anti-KDM5B
Product Number AMAb90860
Isotype IgG1
Validated Applications
IHC, WB
Epitope DGINSLERKLKRRLE
Anti-MACC1Product Name Anti-MACC1
Product Number AMAb90832
Isotype IgG1
Validated Applications
IHC
Anti-MCL1Product Name Anti-MCL1
Product Number AMAb90859
Isotype IgG1
Validated Applications
IHC, WB
Epitope PEEELDGYEP
Anti-MEF2CProduct Name Anti-MEF2C
Product Number AMAb90727
Isotype IgG1
Validated Applications
IHC, WB
Epitope SNPVSSLGNPNLLPL
Anti-MKI67/Ki67Product Name Anti-MKI67
Product Number AMAb90870
Isotype IgG1
Validated Applications
IHC
Epitope PLSLSTCLFGRGIEC
Anti-MKL2Product Name Anti-MKL2
Product Number AMAb90887
Isotype IgG1
Validated Applications
WB
Epitope FASVSPTVPEFLKTP
Anti-MMP9Product Name Anti-MMP9
Product Number AMAb90804
Isotype IgG1
Validated Applications
IHC, WB
Epitope VPDLGRFQTF
Anti-MMP9Product Name Anti-MMP9
Product Number AMAb90806
Isotype IgG2b
Validated Applications
IHC
Epitope RGESKSLGPALLLLQ
Anti-MRC1Product Name Anti-MRC1
Product Number AMAb90746
Isotype IgG2a
Validated Applications
IHC, WB
Anti-MST1R/MSP receptorProduct Name Anti-MST1R
Product Number AMAb90766
Isotype IgG1
Validated Applications
WB
Anti-MTDH/LYRICProduct Name Anti-MTDH
Product Number AMAb90763
Isotype IgG1
Validated Applications
IHC, WB
Anti-NAPRT1Product Name Anti-NAPRT1
Product Number AMAb90725
Isotype IgG1
Validated Applications
IHC, WB
Anti-MMP9Product Name Anti-MMP9
Product Number AMAb90805
Isotype IgG1
Validated Applications
IHC, WB
Epitope RGESKSLGPALLLLQ
Anti-MTDH/LYRICProduct Name Anti-MTDH
Product Number AMAb90762
Isotype IgG2a
Validated Applications
IHC, WB
Anti-NAPRT1Product Name Anti-NAPRT1
Product Number AMAb90823
Isotype IgG1
Validated Applications
IHC, WB
Epitope PAFFEHLRALDCSEV
Anti-NECAB1Product Name Anti-NECAB1
Product Number AMAb90798
Isotype IgG1
Validated Applications
IHC, WB
Epitope SIQWPGKRSS
Anti-NECAB1Product Name Anti-NECAB1
Product Number AMAb90800
Isotype IgG2a
Validated Applications
IHC, WB
Epitope SIQWPGKRSS
Anti-PCM1Product Name Anti-PCM1
Product Number AMAb90565
Isotype IgG1
Validated Applications
IHC, WB
Epitope RQRALYALQD
Anti-PBRM1/Polybromo 1Product Name Anti-PBRM1
Product Number AMAb90690
Isotype IgG1
Validated Applications
IHC, WB
Anti-NECAB2Product Name Anti-NECAB2
Product Number AMAb90808
Isotype IgG1
Validated Applications
IHC
Epitope IGRLESKALWFDLQQ
Anti-NES/NestinProduct Name Anti-NES
Product Number AMAb90556
Isotype IgG1
Validated Applications
IHC, WB
Anti-P4HA2Product Name Anti-P4HA2
Product Number AMAb90710
Isotype IgG1
Validated Applications
IHC, WB
Anti-NECAB1Product Name Anti-NECAB1
Product Number AMAb90801
Isotype IgG2b
Validated Applications
IHC, WB
Epitope SIQWPGKRSS
Anti-NLRP3/NACHTProduct Name Anti-NLRP3
Product Number AMAb90569
Isotype IgG1
Validated Applications
WB
Anti-OCLN/OccludinProduct Name Anti-OCLN
Product Number AMAb90889
Isotype IgG2a
Validated Applications
IHC, WB
Epitope TSPVDDFRQPRYSSG
Anti-OCLN/OccludinProduct Name Anti-OCLN
Product Number AMAb90890
Isotype IgG2a
Validated Applications
IHC, WB
Epitope NDKRFYPESSYKSTP
Anti-OCLN/OccludinProduct Name Anti-OCLN
Product Number AMAb90893
Isotype IgG1
Validated Applications
IHC, WB
Epitope RYSSGGNFETPSKRA
Anti-PGAM5
Anti-PHGDH/3-PGDHProduct Name Anti-PHGDH
Product Number AMAb90786
Isotype IgG1
Validated Applications
IHC, WB
Anti-PLA2R1/PLA2RProduct Name Anti-PLA2R1
Product Number AMAb90772
Isotype IgG1
Validated Applications
IHC, WB
Epitope KIPVSFEWSN
Anti-PODXL/Podocalyxin Ref 1
Product Name Anti-PODXL
Product Number AMAb90667
Isotype IgG1
Validated Applications
IHC, WB
Epitope IHTKLPAKDVYERLK
Anti-RBM3 Ref 2,3,4,5,6,7,8
Product Name Anti-RBM3
Product Number AMAb90655
Isotype IgG1
Validated Applications
IHC, WB
Anti-RESTProduct Name Anti-REST
Product Number AMAb90740
Isotype IgG1
Validated Applications
IHC
Anti-PLA2R1/PLA2RProduct Name Anti-PLA2R1
Product Number AMAb90775
Isotype IgG1
Validated Applications
IHC, WB
Epitope VKNCEERLFYICKKA
Anti-PODXL/PodocalyxinProduct Name Anti-PODXL
Product Number AMAb90643
Isotype IgG2a
Validated Applications
IHC, WB
Epitope GASDEKLISLICRAV
Anti-PODXL/PodocalyxinProduct Name Anti-PODXL
Product Number AMAb90644
Isotype IgG2b
Validated Applications
IHC, WB
Epitope PAKDVYERLKDKWDE
Anti-RHOT1/MIRO-1Product Name Anti-RHOT1
Product Number AMAb90852
Isotype IgG1
Validated Applications
IHC, WB
Epitope VTSRWIPLIN
Product Name Anti-PGAM5
Product Number AMAb90803
Isotype IgG1
Validated Applications
IHC, WB
Epitope NWDRREPLSLINVRK
Anti-S100A4/CalvasculinProduct Name Anti-S100A4
Product Number AMAb90596
Isotype IgG1
Validated Applications
IHC, WB
Epitope KFKLNKSELKELLTR
Anti-SATB2 Ref 9,10,11,12
Product Name Anti-SATB2
Product Number AMAb90635
Isotype IgG1
Validated Applications
IHC, WB
Epitope LVNLRAMQNFLNLPE
Anti-RUNX2/AML-3Product Name Anti-RUNX2
Product Number AMAb90594
Isotype IgG1
Validated Applications
IHC, WB
Anti-RHOT1/MIRO-1Product Name Anti-RHOT1
Product Number AMAb90854
Isotype IgG1
Validated Applications
IHC
Epitope ERTDKDSRLP
Anti-RNASE7Product Name Anti-RNASE7
Product Number AMAb90583
Isotype IgG2a
Validated Applications
IHC, WB
Epitope KGMTSSQWFKIQHMQ
Anti-RNASE7Product Name Anti-RNASE7
Product Number AMAb90582
Isotype IgG1
Validated Applications
IHC
Epitope LTMCKLTSGKYPNCR
Anti-RUNX2/AML-3Product Name Anti-RUNX2
Product Number AMAb90591
Isotype IgG2a
Validated Applications
IHC
Anti-S100A4/CalvasculinProduct Name Anti-S100A4
Product Number AMAb90598
Isotype IgG2b
Validated Applications
IHC, WB
Epitope CNEFFEGFPDKQPRKK
Anti-S100A4/CalvasculinProduct Name Anti-S100A4
Product Number AMAb90599
Isotype IgG1
Validated Applications
IHC, WB
Epitope CNEFFEGFPD
Anti-SATB2Product Name Anti-SATB2
Product Number AMAb90678
Isotype IgG2a
Validated Applications
IHC, WB
Epitope KCQEFGRWYKKYKKI
Anti-SCGN/Secretagogin Ref 13
Product Name Anti-SCGN
Product Number AMAb90630
Isotype IgG1
Validated Applications
IHC, WB
Anti-SDHBProduct Name Anti-SDHB
Product Number AMAb90705
Isotype IgG2a
Validated Applications
IHC, WB
Anti-SIX1Product Name Anti-SIX1
Product Number AMAb90544
Isotype IgG1
Validated Applications
IHC, WB
Anti-SLC22A2/OCT2Product Name Anti-SLC22A2
Product Number AMAb90791
Isotype IgG1
Validated Applications
IHC
Epitope KNAEAMRIIKHIAKK
Anti-SATB2Product Name Anti-SATB2
Product Number AMAb90679
Isotype IgG1
Validated Applications
IHC, WB
Epitope SLGKTNEQSPHSQIH
Anti-SATB2Product Name Anti-SATB2
Product Number AMAb90680
Isotype IgG1
Validated Applications
IHC, WB
Epitope KCQEFGRWYKKYKKI
Anti-SATB2Product Name Anti-SATB2
Product Number AMAb90682
Isotype IgG1
Validated Applications
IHC, WB
Epitope HSTPIRNQVPALQPI
Anti-SCGN/SecretagoginProduct Name Anti-SCGN
Product Number AMAb90632
Isotype IgG2a
Validated Applications
IHC
Anti-SDHBProduct Name Anti-SDHB
Product Number AMAb90706
Isotype IgG1
Validated Applications
IHC, WB
Epitope EEREKLDGLYECILC
Anti-SDHBProduct Name Anti-SDHB
Product Number AMAb90708
Isotype IgG1
Validated Applications
IHC, WB
Epitope RLAKLQDPFS
Anti-SLC22A2/OCT2Product Name Anti-SLC22A2
Product Number AMAb90792
Isotype IgG2b
Validated Applications
IHC
Epitope KNAEAMRIIKHIAKK
Anti-SLC27A5/BACSProduct Name Anti-SLC27A5
Product Number AMAb90572
Isotype IgG1
Validated Applications
IHC, WB
Epitope RCFYLSHTSP
Anti-SOX9Product Name Anti-SOX9
Product Number AMAb90795
Isotype IgG2a
Validated Applications
IHC, WB
Epitope SQRTHIKTEQLSPSH
Anti-STX7/Syntaxin-7Product Name Anti-STX7
Product Number AMAb90616
Isotype IgG1
Validated Applications
IHC, WB
Anti-SLC27A5/BACSProduct Name Anti-SLC27A5
Product Number AMAb90574
Isotype IgG1
Validated Applications
IHC, WB
Epitope ESLEEILPKL
Anti-SLC27A5/BACSProduct Name Anti-SLC27A5
Product Number AMAb90575
Isotype IgG1
Validated Applications
IHC, WB
Epitope SHPVPADLRA
Anti-SOX11Product Name Anti-SOX11
Product Number AMAb90501
Isotype IgG2a
Validated Applications
IHC, WB
Epitope IPFIREAERL
Anti-SOX11 Ref 14
Product Name Anti-SOX11
Product Number AMAb90502
Isotype IgG2a
Validated Applications
IHC, WB
Epitope IPFIREAERL
Anti-STAT3 Product Name Anti-STAT3
Product Number AMAb90776
Isotype IgG1
Validated Applications
IHC, WB
Epitope TKFICVTPTTCSNTI
Anti-STAT3 Product Name Anti-STAT3
Product Number AMAb90777
Isotype IgG1
Validated Applications
IHC, WB
Epitope TNILVSPLVY
Anti-TET1Product Name Anti-TET1
Product Number AMAb90604
Isotype IgG1
Validated Applications
IHC
Anti-TG/ThyroglobulinProduct Name Anti-TG
Product Number AMAb90523
Isotype IgG2b
Validated Applications
IHC, WB
Anti-TSPAN7/Tetraspanin-7Product Name Anti-TSPAN7
Product Number AMAb90621
Isotype IgG1
Validated Applications
IHC, WB
Epitope NDERSRAVDHVQRSL
Anti-TSPAN7/Tetraspanin-7Product Name Anti-TSPAN7
Product Number AMAb90624
Isotype IgG1
Validated Applications
IHC
Epitope TDCNPQDLHNLTVAA
Anti-TTR/TransthyretinProduct Name Anti-TTR
Product Number AMAb90649
Isotype IgG1
Validated Applications
IHC, WB
Anti-USP46Product Name Anti-USP46
Product Number AMAb90722
Isotype IgG2b
Validated Applications
WB
Anti-USP46Product Name Anti-USP46
Product Number AMAb90723
Isotype IgG2a
Validated Applications
WB
Anti-VANGL1Product Name Anti-VANGL1
Product Number AMAb90600
Isotype IgG1
Validated Applications
WB
Anti-THY1/CD90Product Name Anti-THY1
Product Number AMAb90844
Isotype IgG2b
Validated Applications
IHC, WB
Epitope ACLVDQSLRLDCRHE
Anti-THY1/CD90Product Name Anti-THY1
Product Number AMAb90846
Isotype IgG1
Validated Applications
IHC, WB
Epitope ACLVDQSLRLDCRHE
Anti-VIM/VimentinProduct Name Anti-VIM
Product Number AMAb90516
Isotype IgG1
Validated Applications
IHC, WB
Anti-WWTR1Product Name Anti-WWTR1
Product Number AMAb90729
Isotype IgG1
Validated Applications
WB
Anti-ZEB1Product Name Anti-ZEB1
Product Number AMAb90510
Isotype IgG1
Validated Applications
IHC, WB
Anti-ZNF703Product Name Anti-ZNF703
Product Number AMAb90789
Isotype IgG1
Validated Applications
IHC
Epitope PGDKAGFRVP
Anti-WHSC1Product Name Anti-WHSC1
Product Number AMAb90848
Isotype IgG1
Validated Applications
IHC
Epitope RVFNGEPGAHDAKLR
Anti-WHSC1Product Name Anti-WHSC1
Product Number AMAb90851
Isotype IgG2b
Validated Applications
IHC, WB
Epitope ALPFIPADKL
Anti-WWTR1Product Name Anti-WWTR1
Product Number AMAb90730
Isotype IgG1
Validated Applications
IHC, WB
Epitope SSWRKKILPESFFKE
1. Boman K, Larsson AH, Segersten U, Kuteeva E, Johannesson H, Nodin B, Eberhard J, Uhlén M, Malmström PU, Jirström K.Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.Br J Cancer. 2013 Jun 11;108(11):2321-8.
2. Ehlén A, Brennan DJ, Nodin B, O’Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brändstedt J, Uhlén M, Pontén F, Jirström KExpression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.J Transl Med 2010 Aug 20;8:78
3. Jonsson L, Gaber A, Ulmert D, Uhlén M, Bjartell A, Jirström KHigh RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease pro-gression.Diagn Pathol 2011 Sep 28;6:91
4. Nodin B, Fridberg M, Jonsson L, Bergman J, Uhlén M, Jirström KHigh MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanomaDiagn Pathol 782. Epub 2012 Jul 17.
5. Jonsson L, Bergman J, Nodin B, Manjer J, Pontén F, Uhlén M, Jirström KLow RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study.J Transl Med 2011 Jul 21;9:114
6. Ehlén Å, Nodin B, Rexhepaj E, Brändstedt J, Uhlén M, Alvarado-Kristensson M, Pontén F, Brennan DJ, Jirström KRBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer.Transl Oncol 2011 Aug;4(4):212-21
7. Hjelm B, Brennan DJ, Zendehrokh N, Eberhard J, Nodin B, Gaber A, Pontén F, Johannesson H, Smaragdi K, Frantz C, Hober S, Johnson LB, Påhlman S, Jirström K, Uhlen MHigh nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer.Proteomics Clin Appl 2011 Dec;5(11-12):624-35
8. Boman K, Segersten U, Ahlgren G, Eberhard J, Uhlén M, Jirström K, Malmström PU.Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial blad-der cancer.BMC Urol. 2013 Apr 8;13:17.
9. Eberhard J, Gaber A, Wangefjord S, Nodin B, Uhlén M, Ericson Lindquist K, Jirström KA cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer.Br J Cancer 2012 Feb 28;106(5):931-8
10. Kiflemariam S, Andersson S, Asplund A, Pontén F, Sjöblom TScalable in situ hybridization on tissue arrays for validation of novel cancer and tissue-specific biomarkers.PLoS One 2012;7(3):e32927
11. Rockberg J, Löfblom J, Hjelm B, Uhlén M, Ståhl SEpitope mapping of antibodies using bacterial surface display.Nat Methods 2008 Dec;5(12):1039-45
12. Dragomir A, de Wit M, Johansson C, Uhlén M, Pontén F.The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results from a pathology-based clinical prospective study.American Journal of Clinical Pathology 2013 Accepted Oct
13. Shi TJ, Xiang Q, Zhang MD, Tortoriello G, Hammarberg H, Mulder J, Fried K, Wagner L, Josephson A, Uhlén M, Harkany T, Hökfelt T.Secretagogin is expressed in sensory CGRP neurons and in spinal cord of mouse and complements other calcium-binding proteins, with a note on rat and human.Mol Pain 2012 Oct 29;8:80
14. Soldini D, Valera A, Solé C, Palomero J, Amador V, Martin-Subero JI, Ribera-Cortada I, Royo C, Salaverria I, Beà S, Gon-zalvo E, Johannesson H, Herrera M, Colomo L, Martinez A, Campo E.Assessment of SOX11 Expression in Routine Lymphoma Tissue Sections: Characterization of New Monoclonal Antibodies for Diagnosis of Mantle Cell Lymphoma.Am J Surg Pathol. 2013 Oct 18.
REFERENCES
Atlas Antibodies ABAlbaNova University CenterSE-106 91 Stockholm, Swedenatlasantibodies.com
Phone +46(0)8 54 59 58 50Fax +46(0)8 54 59 58 [email protected]@atlasantibodies.com
atlasantibodies.comOur website provides you with easy access to all characterization data, and online ordering via our web shop. You can also send your order to [email protected].
Or send an e-mail to [email protected] to discuss any matters regarding use of antibodies.You’ll find we’re Totally Human.